Článek

Understanding the U.K.’s International Recognition Procedure

Datum aktualizace October 13, 2026
Learn how the MHRA International Recognition Procedure works, who can apply, Recognition A and B timelines and how it can speed up U.K. market access. 
Since the United Kingdom’s exit from the European Union in 2020, there have been numerous changes in the procedures implemented to ensure that there is access to medicines for U.K. patients. One area of interest and a growing topic of discussion in the pharmaceutical industry is the International Recognition Procedure (IRP), which was introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) on January 1, 2024, replacing and expanding on the EC Decision Reliance Procedure (ECDRP).1 

The introduction of the IRP has brought opportunities for faster market access for manufacturers by enabling the MHRA to conduct more targeted assessments by taking into account the expertise and decision-making of trusted regulatory partners. 

The IRP also allows the MHRA to perform product lifecycle activities utilized for post-approval submissions, including line extensions, variations (Type IB and Type II) and renewals for a medicinal product with an existing Marketing Authorisation (MA) granted by one of the MHRA’s acceptable reference regulators (RRs), which include: 

 

Country or jurisdiction Regulatory authority
Australia Therapeutic Goods Administration
Canada Health Canada
Switzerland Swissmedic
Singapore Health Sciences Authority
Japan Pharmaceuticals and Medical Devices Agency
United States Food and Drug Administration
European Union/European Economic Area European Medicines Agency and Member State Competent Authorities of the EU, Norway, Iceland and Liechtenstein. (This includes approvals through the centralized, MRP/DCP and individual member state national routes.)

The IRP may also be used for Access Consortium approvals that did not include the MHRA as part of the work-sharing procedure.1

IRP process

New IRP marketing authorization application (MAA)

A new MA may be achieved via one of two possible recognition pathways: 

  • Recognition A is applicable if the reference regulator MA has been granted within the previous 2 years1 (60-day procedure, no clock stop).
  • Recognition B is applicable if the reference regulator MA has been granted within the previous 10 years and fulfills at least 1 of the 24 listed criteria (110-day procedure with no more than 1 clock stop). If there are outstanding Major Objections at Day 110, formal advice on approvability will be sought from the CHM, and the timetable will revert to the national 210-day timetable.1 

Update: As of July 13, 2026, the MHRA has shortened the Recognition B window. The reference regulator’s approval must now have been granted within the previous 5 years, rather than 10 years. Recognition A is unchanged at 2 years. A transition phase allowed applicants to use the previous process until Aug. 31, 2026.2

Post-authorization IRP applications: Variations and renewals

The IRP can be used during the lifecycle of products that have been initially authorized or subsequently varied via standalone national, MRDCRP or ECDRP routes. Conversely, where a product has been authorized via the IRP, it is acceptable to submit standalone national post-authorization procedures, including variations.1 

Full details of the IRP submission process and requirements are provided on the MHRA website: 

Who can apply?

To ensure that the applicant/Marketing Authorization Holder (MAH) can fulfill the submission requirements as well as all their legal obligations as holder of an MA, such as the obligations stated in Regulations 74 and 75 of the Human Medicines Regulations 2012, the applicant/MAH must be established in the U.K. (Great Britain or Northern Ireland) or in the EU/EEA, and it is anticipated that the applicant for an IRP application is the same company or belongs to the same (legal) group of companies as the MAH of the RR procedure.1 

In some situations, it may be possible to accept applications from third parties if the applicant can demonstrate and provide written assurance that all the legal obligations can be met at submission, during the assessment process and throughout the life of the MA.1

Key advantages of using the IRP

Expansion of international collaborations

The IRP allows the MHRA to consider the decisions of trusted regulatory partners both from the EU and globally, expanding international collaborations and reducing repetition of work for the health authorities and MAHs alike.1

Fast market access

Navigating the regulatory processes in the lead-up to the submission can be challenging, and submitting a marketing application is a significant undertaking, involving multiple stakeholders over a period of up to 2 years (if all goes to plan). 

Expedited approval with review times of 60 days (Route A) and 110 days (Route B) is significantly shorter than the MHRA national route for MAA,1 which has a 210-day timetable. This will allow quicker market access for medicines authorized outside of the EU and reduce assessment pressure and time burden on the MHRA.

MHRA support

For MAAs, the MHRA requires an online eligibility form, which determines the suitability for recognition pathway A or B. Applicants intending to submit via the IRP have the option of requesting pre-submission advice through a form and returning this to presubmission@mhra.gov.uk3

The IRP has been operational since January 1, 2024. In December 2024, a total of 265 IRP submissions (Type IB: 190; Type II: 75) were approved, with 95% to 97% granted within the statutory timeframe.4

Other considerations

Eligibility constraints

The IRP is only applicable to:

  • Chemical and biological new active substances and known active substances 
  • Generic applications 
  • Hybrid applications 
  • Biosimilar applications 
  • New fixed combination product applications 

It is not applicable to:

  • Bibliographic applications 
  • Traditional herbal registrations 
  • Homeopathic registrations 
As of October 2026, the MHRA also excludes emergency approvals and cancelled authorizations, and refused or withdrawn national applications cannot be resubmitted through the IRP. Reference regulator assessments that rely on, or recognize, an authorization from another territory cannot be used either.2 


Zřeknutí se:
Informace v tomto článku mají za cíl informovat čtenáře o tématu souvisejícím se schopnostmi společnosti Cencora a nejsou právním ani nákupním poradenstvím. Společnost Cencora, Inc. doporučuje čtenářům, aby si prostudovali odkazy citované v tomto článku a při rozhodování využili své vlastní znalosti a zkušenosti.
 

 

Jsme tu, abychom vám pomohli

Spojte se s naším týmem ještě dnes a zjistěte více o tom, jak společnost Cencora pomáhá utvářet budoucnost zdravotnictví.

Related solutions

Související zdroje

Článek

Překonání výzev v raném vývoji: Poznatky z BIO panelu

Článek

Klíčové poznatky z technického pilotního projektu EU eCTD 4.0

Článek

Jak se vypořádat s dnešními výzvami v oblasti regulatorního publikování: Jak se společnosti zabývající se přírodními vědami přizpůsobují

References 
1. Medicines and Healthcare products Regulatory Agency. "International Recognition Procedure." GOV.UK, Jan. 29, 2024.
2. Medicines and Healthcare products Regulatory Agency. "International Recognition Procedure." GOV.UK, updated Oct. 9, 2026.
3. Medicines and Healthcare products Regulatory Agency. "Pre-Submission Advice & Support for Innovative Medicines." GOV.UK, Aug. 13, 2024.
4. Medicines and Healthcare products Regulatory Agency. "Assessment of New Marketing Authorisation Applications and Variations." December 2024.